British guideline on the management of asthma: SIGN Clinical Guideline 141, 2014

James, David; Lyttle, Mark D

doi:10.1136/archdischild-2015-310145

Cited by 45 publications

(44 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current guidelines recommend the combined use of glucocorticoids and beta2 agonists as the preferred therapy for asthmatic children during acute exacerbation [3,4]. The glucocorticoid and beta2 agonist therapies are effective at controlling airway inflammation, reducing asthma symptoms, decreasing airway hyper-responsiveness and reducing the frequency and severity of exacerbations as well as asthma mortality.…”

mentioning

confidence: 99%

Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation

Yang

Zhang

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Inhaled budesonide and salbutamol represent the most important and frequently used drugs in asthmatic children during acute exacerbation. However, there is still no consensus about their resulting metabolic derangements; thus, this study was conducted to determine the distinct metabolic profiles of these two drugs. A total of 69 children with asthma during acute exacerbation were included, and their serum and urine were investigated using high-resolution nuclear magnetic resonance (NMR). A metabolomics analysis was performed using a principal component analysis and orthogonal signal correction-partial least squares using SIMCA-P. The different metabolites were identified, and the distinct metabolic profiles were analysed using MetPA. A high-resolution NMR-based serum and urine metabolomics approach was established to study the overall metabolic changes after inhaled budesonide and salbutamol in asthmatic children during acute exacerbation. The perturbed metabolites included 22 different metabolites in the serum and 21 metabolites in the urine. Based on an integrated analysis, the changed metabolites included the following: increased 4-hydroxybutyrate, lactate, cis-aconitate, 5-hydroxyindoleacetate, taurine, trans-4-hydroxy-l-proline, tiglylglycine, 3-hydroxybutyrate, 3-methylhistidine, glucose, cis-aconitate, 2-deoxyinosine and 2-aminoadipate; and decreased alanine, glycerol, arginine, glycylproline, 2-hydroxy-3-methylvalerate, creatine, citrulline, glutamate, asparagine, 2-hydroxyvalerate, citrate, homoserine, histamine, sn-glycero-3-phosphocholine, sarcosine, ornithine, creatinine, glycine, isoleucine and trimethylamine N-oxide. The MetPA analysis revealed seven involved metabolic pathways: arginine and proline metabolism; taurine and hypotaurine metabolism; glycine, serine and threonine metabolism; glyoxylate and dicarboxylate metabolism; methane metabolism; citrate cycle; and pyruvate metabolism. The perturbed metabolic profiles suggest potential metabolic reprogramming associated with a combination treatment of inhaled budesonide and salbutamol in asthmatic children.Glucocorticoids and beta2 agonists represent the most important and frequently used drugs for symptom control in asthmatic children during acute exacerbation [1,2]. Current guidelines recommend the combined use of glucocorticoids and beta2 agonists as the preferred therapy for asthmatic children during acute exacerbation [3,4]. The glucocorticoid and beta2 agonist therapies are effective at controlling airway inflammation, reducing asthma symptoms, decreasing airway hyper-responsiveness and reducing the frequency and severity of exacerbations as well as asthma mortality. Despite their undoubted effectiveness and safety, there is still no consensus about the resulting metabolic derangements, including the development of dyslipidaemia, insulin resistance, glucose intolerance, diabetes, central adiposity and skeletal muscle wasting [5][6][7].Both glucocorticoids and beta2 agonists have the potential to influence glucose, lipid and protein...

show abstract

mentioning

confidence: 99%

Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation

Yang

Zhang

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Se seleccionaron las guías con mejor puntuación AGREE-II a nivel mundial y se tomó en cuenta su adaptabilidad a la realidad mexicana. De tal forma, se eligieron como guías madre las siguientes: British Thoracic Society Asthma Guideline (BTS) 2014, 3 tomando nota de los cambios en su actualización de 2016; 4 Global Initiative on Asthma (GINA) 2015, actualizada a 2016; 5 y la Guía Española del Manejo del Asma (GEMA) 2015. 6 Universidad "Juárez" Autónoma de Tabasco.…”

Section: Pasos En La Elaboración De Guima 2017unclassified

“…Hubo buena concordancia entre las evaluaciones AGREE-II por guía y en caso de discordancia se discutió hasta llegar a consenso con todo el grupo nuclear. Finalmente, las tres guías con mejor puntuación que se eligieron como guías madre para esta Guía Mexicana del Asma 2017 (GUIMA 2017) fueron British Thoracic Society Asthma Guideline (BTS) 2014, 3 considerando los cambios en su actualización en 2016; 4 Global Initiative on Asthma (GINA) 2015, actualizada a 2016; 5 y la Guía Española del Manejo del Asma (GEMA) 2015. 6 Simultáneamente, el grupo nuclear de GUIMA 2017 desarrolló el documento de alcances (scope) y el mapa de decisiones en el diagnóstico y el tratamiento del asma y de la crisis asmática.…”

Section: Evaluación De La Calidad De Guías De Práctica Clínica: Agree-iiunclassified

“…Désirée Larenas-Linnemann, 1 Jorge Salas-Hernández, 2 Juan Carlos Vázquez-García, 3 Ignacio Ortiz-Aldana, 4 Margarita Fernández-Vega, 5 Blanca Estela Del Río-Navarro, 6 María del Carmen Cano-Salas, 7 Jorge Agustín Luna-Pech, 8 José Antonio Ortega-Martell, 9 Jade Romero-Lombard, 10 Erika del Carmen López-Estrada, 11 Jimena Villaverde-Rosas, 12 José Luis Mayorga-Butrón, 13 Mario Humberto Vargas-Becerra, 14 Martín BedollaBarajas, 15 Noel Rodríguez-Pérez, 16 Ambrocio Aguilar-Aranda, 17 Carlos Adrián Jiménez-González, 18 Carlos García-Bolaños, 19 Claudia GarridoGalindo, 20 David Alejandro Mendoza-Hernández, 21 Enrique Mendoza-López, 22 Gerardo López-Pérez, 21 Guillermo Hideo Wakida-Kuzonoki, 23 Héctor Hernán Ruiz-Gutiérrez, 24 Héctor León-Molina, 25 Héctor Martínez-De la Lanza, 26 Héctor Stone-Aguilar, 27 Javier Gómez-Vera, 28 Jorge…”

unclassified

See 1 more Smart Citation

Guía Mexicana del Asma: GUIMA 2017

Larenas-Linnemann¹,

Salas-Hernández²,

Vázquez-García³

et al. 2017

RAM

View full text Add to dashboard Cite

Este artículo debe citarse como: Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE, et al. Guía Mexicana del Asma 2017. Rev Alerg Mex. 2017;64 Supl 1:s11-s128. AbstractBackground: The need for a national guideline, with a broad basis among specialists and primary care physicians was felt in Mexico, to try unifying asthma management. As several high-quality asthma guidelines exist worldwide, it was decided to select the best three for transculturation. Methods: Following the internationally recommended methodology for guideline transculturation, ADAPTE, a literature search for asthma guidelines, published 1-1-2007 through 31-12-2015 was conducted. AGREE-II evaluations yielded 3/40 most suitable for transculturation. Their compound evidence was fused with local reality, patient preference, cost and safety considerations to draft the guideline document. Subsequently, this was adjusted by physicians from 12 national medical societies in several rounds of a Delphi process and 3 face-to-face meetings to reach the final version. Results: Evidence was fused from British Thoracic Society Asthma Guideline 2014, Global Initiative on Asthma 2015, and Guía Española del Manejo del Asma 2015 (2016 updates included). After 3 Delphi-rounds we developed an evidence-based document taking into account patient characteristics, including age, treatment costs and safety and best locally available medication. Conclusion: In cooperation pulmonologists, allergists, ENT physicians, paediatricians and GPs were able to develop an evidence-based document for the prevention, diagnosis and treatment of asthma and its exacerbations in Mexico.Keywords: Clinical practice guideline; Asthma; Asthmatic exacerbation; Bronchodilator; Inhaled corticosteroid; Spirometry; Immunotherapy. IntroducciónLa presentación de este documento muestra la importancia del asma en México por su alta prevalencia, pero también por su subdiagnóstico y tratamiento deficiente, que propician un mal control de los pacientes con asma, crisis más frecuentes y sintomatología activa. En consecuencia, el asma tiene un impacto socioeconómico considerable para el paciente y la sociedad en su conjunto, al igual que afecta la calidad de vida del paciente y su familia. En México, el paciente con asma puede recibir atención médica en los ámbitos pú-blico o privado, en los diferentes niveles de salud y por múltiples especialidades. Todas estas particularidades de la situación nacional indican la necesidad de un documento guía actualizado, con base amplia en múltiples gremios médicos, tanto de primer nivel de atención como de especialidad.El objetivo de la GUIMA 2017 es facilitar la reducción de la morbimortalidad por asma en México, no solo al mejorar el conocimiento acerca de esta patología, sino también al ayudar a la parte administrativa del Sector Salud a gestionar la selección y adquisición más precisa de los medicamentos necesarios para su tratamiento a nivel de la salud pública. Para tal fin se ofrecen lineamientos par...

show abstract

“…In addition to these symptoms, the diagnosis of asthma is based on the existence of acute episodes of dyspnea (dyspnea crisis) that are not common in any of the other processes, a concept maintained over the years [1][2][3]. The bronchial hyperresponsiveness (BHR), is responsible for acute and sporadic bronchiospasm, that is, the aforementioned episodes of dyspnea.…”

mentioning

confidence: 99%

Ethiopathogenic mechanisms of bronchial asthma

Muñoz-López¹

2017

J Transl Sci

View full text Add to dashboard Cite

Asthma is the most frequent respiratory process both in pediatric and adult ages, but when sharing symptoms with other processes, sometimes there are certain diagnostic doubts and especially therapeutic. The distinction is the bronchiospasm crisis due to the existence of bronchial hyperresponsiveness, the origin of which may be genetic, which causes the onset of asthma to be at an early age, or caused by inflammation due to exposure to various environmental or infectious irritants. The pathogenesis of both possibilities is the subject of this review insisting on specifying the diagnosis that will lead to appropriate treatment not always based only on anti-inflammatories.

show abstract

British guideline on the management of asthma: SIGN Clinical Guideline 141, 2014

Cited by 45 publications

References 4 publications

Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation

Distinct Metabolic Profile of Inhaled Budesonide and Salbutamol in Asthmatic Children during Acute Exacerbation

Guía Mexicana del Asma: GUIMA 2017

Ethiopathogenic mechanisms of bronchial asthma

Contact Info

Product

Resources

About